Bristol Myers fails in late-stage trial for Merck-partnered anemia therapy in blood cancer

3 hours ago 1

Healthcare

Comments

Bristol Myers Squibb (NYSE:BMY) announced on Friday that its anemia therapy, Reblozyl, developed with Merck (NYSE:MRK), did not meet the main goal in a Phase 3 trial for certain adults with a rare blood cancer type called myelofibrosis.

Citing topline

Recommended For You

More Trending News

Read Entire Article

Bristol Myers fails in late-stage trial for Merck-partnered anemia therapy in blood cancer

Recommended For You

More Trending News

Related

Abbott upgraded to Buy at Jefferies despite underwhelming ou...

Blockchain Association CEO: New crypto laws will make US ‘Cr...

Gold hallmarking made mandatory for 9 carat jewellery

United's effective cost control, improving corporate demand ...

Wall Street is mixed as record highs for S&P and Nasdaq are ...

Hyderabad heavy rains today hits normal life disrupting traf...

The Wealth Company gets SEBI nod to launch mutual fund, aims...

4 Amrit Bharat trains flagged off in Bihar: DRM explains how...

Crispr director George buys $51.5M of shares

SEC's Atkins says he'll proceed carefully on potential 401(k...

Calvin B. Taylor Bankshares declares $0.37 dividend

OpenAI warns that its new ChatGPT Agent has the ability to a...

Mexico City’s Airbnb deal has led years later to ferocious p...

Canadian Banc Corp. PFD declares CAD 0.0538 dividend

Canadian Banc declares CAD 0.1508 dividend

Prime Dividend declares CAD 0.0711 dividend

Adecoagro launches notes offering

US, India lead global list as 539 companies float IPOs in H1...

Bizarre discovery of 21 children in LA home raises questions...

Dell's EPS might double by 2030 due to enterprise AI adoptio...

Trending

Popular

سفیر جدید برزیل استوارنامه خود را تقدیم عراقچی کرد

توانمند سازی صنایع و کارخانجات استان با بهره‌گیری از محصولات...